Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

• Post published:September 6, 2023
• Post category:Press Release

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

• Post published:August 8, 2023
• Post category:Press Release

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

• Post published:July 15, 2023
• Post category:Press Release

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

• Post published:June 27, 2023
• Post category:Press Release

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

• Post published:June 6, 2023
• Post category:Press Release

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

• Post published:June 5, 2023
• Post category:Press Release

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

• Post published:May 31, 2023
• Post category:Press Release

Algernon Pharmaceuticals Announces Closing of Rights Offering

• Post published:May 6, 2023
• Post category:Press Release

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

• Post published:April 20, 2023
• Post category:Press Release

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

• Post published:April 17, 2023
• Post category:Press Release